These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8646294)

  • 1. A pharmacokinetic study of an ion-exchange solvent-detergent-treated high-purity factor VIII concentrate. Haemophilia Directors for Scotland and Northern Ireland.
    Ludlam CA; Lowe GD; Mayne EE
    Transfus Med; 1995 Dec; 5(4):289-92. PubMed ID: 8646294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 degrees C terminal dry heat treatment in patients with haemophilia A.
    Powell JS; Bush M; Harrison J; Abildgaard C; Vosburgh E; Thompson AR; Hurst D
    Haemophilia; 2000 May; 6(3):140-9. PubMed ID: 10792471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/detergent treated plasma derivatives.
    Schwinn H; Smith A; Wolter D
    Arzneimittelforschung; 1989 Oct; 39(10):1302-5. PubMed ID: 2514695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large-scale gel filtration chromatography for the production of a solvent/detergent-treated high-purity factor VIII concentrate.
    Dengler T; Stöcker U; Kellner S; Fürst G
    Vox Sang; 1990; 58(4):257-63. PubMed ID: 1697997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A.
    Dmoszynska A; Hellmann A; Baglin T; O'Shaugnessy D; Trelinski J; Kuliczkowski K; Kloczko J; Hay C; Zawilska K; Makris M; Shaikh-Zaidi R; Gascoigne E; Dash C
    Haemophilia; 2011 Mar; 17(2):185-90. PubMed ID: 21070496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product.
    Yee TT; Williams MD; Hill FG; Lee CA; Pasi KJ
    Thromb Haemost; 1997 Sep; 78(3):1027-9. PubMed ID: 9308748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII.
    Foster PR; Griffin BD; Bienek C; McIntosh RV; MacGregor IR; Somerville RA; Steele PJ; Reichl HE
    Vox Sang; 2004 Feb; 86(2):92-9. PubMed ID: 15023177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of the hepatitis A epidemics in hemophiliacs in Europe.
    Vermylen J; Peerlinck K
    Vox Sang; 1994; 67 Suppl 4():8-11; discussion 24-6. PubMed ID: 7831867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation of intermediate-purity factor VIII concentrate by direct gel filtration of cryoprecipitate.
    Teh LC
    Vox Sang; 1993; 65(4):251-7. PubMed ID: 8310677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate.
    Lemon SM; Murphy PC; Smith A; Zou J; Hammon J; Robinson S; Horowitz B
    J Med Virol; 1994 May; 43(1):44-9. PubMed ID: 8083647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
    Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison.
    Hay CR; Ludlam CA; Lowe GD; Mayne EE; Lee RJ; Prescott RJ; Lee CA
    Br J Haematol; 1998 Jun; 101(4):632-7. PubMed ID: 9674733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group.
    Mannucci PM; Gdovin S; Gringeri A; Colombo M; Mele A; Schinaia N; Ciavarella N; Emerson SU; Purcell RH
    Ann Intern Med; 1994 Jan; 120(1):1-7. PubMed ID: 7504424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII.
    El-Ekiaby M; Goubran HA; Radosevich M; Abd-Allah A; El-Ekiaby A; Burnouf T
    Haemophilia; 2011 Sep; 17(5):e884-8. PubMed ID: 21371202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary clinical experience: pharmacokinetics and tolerance of a double-virus-inactivated factor VIII preparation.
    Martinowitz U
    Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S84-5. PubMed ID: 7495976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
    Gazengel C; Fischer AM; Schlegel N; Rothschild C; Torchet MF; Dautzenberg MD; Aujard Y
    Nouv Rev Fr Hematol (1978); 1988; 30(4):225-7. PubMed ID: 3143100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates.
    Morfini M; Mannucci PM; Longo G; Cinotti S; Messori A
    Thromb Res; 1991 Feb; 61(3):285-90. PubMed ID: 1902997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.